Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
61.7M
-
Number of holders
-
272
-
Total 13F shares, excl. options
-
71M
-
Shares change
-
+5.99M
-
Total reported value, excl. options
-
$3.92B
-
Value change
-
+$345M
-
Put/Call ratio
-
1.1
-
Number of buys
-
169
-
Number of sells
-
-123
-
Price
-
$55.27
Significant Holders of Protagonist Therapeutics, Inc - COMMON STOCK (PTGX) as of Q2 2025
339 filings reported holding PTGX - Protagonist Therapeutics, Inc - COMMON STOCK as of Q2 2025.
Protagonist Therapeutics, Inc - COMMON STOCK (PTGX) has 272 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71M shares
.
Largest 10 shareholders include BlackRock, Inc. (9.63M shares), FARALLON CAPITAL MANAGEMENT LLC (6.17M shares), RTW INVESTMENTS, LP (5.76M shares), VANGUARD GROUP INC (4.36M shares), Deep Track Capital, LP (3.25M shares), BVF INC/IL (3.21M shares), STATE STREET CORP (3.21M shares), UBS Group AG (2.5M shares), JOHNSON & JOHNSON (2.45M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.44M shares).
This table shows the top 272 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.